Isolated antigenic oncogene peptide fragments and uses

Details Isolated antigenic oncogene peptide fragments and uses Isolated antigenic oncogene peptide fragments and uses

1994-02-10

1996-08-27

Low, Christopher S. F.

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

8 to 10 amino acid residues in defined sequence

530300, 530403, 514 2, 514 15, 930230, 4241841, 4241851, 4242771, 4241551, 4241541, 4241741, A61K 3808, C07K 412

Patent

active

055502148

ABSTRACT:
An isolated antigenic peptide fragment that is an isolated oncogene protein fragment is disclosed. The isolated peptide fragment of the invention is a peptide either 9 or 10 amino acid residues in length that includes at least a leucine residue at the C- terminus (i.e., position 9 or position 10). The peptide fragment is capable of binding in an HLA-A2 binding cleft and is capable of stimulating proliferation of at least one tumor-specific cytotoxic T-lymphocyte. Preferred peptides further include an isoleucine residue at position 2 and a valine residue at position 6. The most preferred isolated peptides can stimulate proliferation of cytotoxic T-lymphocytes obtainable from peripheral blood lymphocytes, ovarian tumors, breast tumors, gastric tumors, non-small cell lung tumors, pancreatic tumors, colon tumors, gliomas, bladder tumors, endometrial tumors and neuroblastomas. The preferred isolated peptide of the invention is a mutant peptide defined by SEQ ID NO.:2 or its functional equivalents.
Isolated cytotoxic T-lymphocytes capable of recognizing isolated peptides of the invention, particularly the HER2
eu mutant peptide are disclosed. These lymphocytes are especially useful for killing tumors or other cells which present on their surfaces the antigenic peptides of the invention. In particular, the lymphocytes are obtainable from ovarian tumor cells, breast tumor cells and non-small-cell lung tumor cells.
A method of stimulating proliferation of tumor-specific cytotoxic T-lymphocytes is described. This method includes obtaining lymphocytes from tumor tissue and contacting the lymphocytes with a peptide of the invention under conditions sufficient for the cytotoxic T-lymphocytes to proliferate. Therapeutically effective compositions containing the HER2
eu peptides are also described.

REFERENCES:
patent: 4968603 (1990-11-01), Slamon et al.
Webster's II New Riverside University Dictionary, Houghton Miflin Co., Boston, MA. p. 433.
Nijman et al., "Characterization of cytotoxic T Lymphocyte Epitopes of a self-protein, p53, and a non-self-protein, influenza matrix: relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptides", Jour. of Immun., 14:121-126, 1993.
Parker et al., "Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2", vol. 149, 3680-3587, No. 11, Dec. 1, 1992 (J. Immunol.).
Parker et al., "Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains", The Journal of Immunology, vol. 152, No. 1, Jan. 1, 1994.
Peoples et al., "Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2
eu-derived peptide", Proc. Natl. Sci., vol. 92, pp. 432-436, Jan. 1995.
Sauma et al., "Recognition by HLA-A2-restricted cytotoxic T Lymphocytes of endogenously generated and exogenously provided synthetic peptide analogues of the influenza A virus matrix protein", Human Immunology, 37, pp. 252-258, 1993.
Yoshino et al., "HER2
eu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer", Cancer research, 54, 3387-3390, Jul. 1, 1994.
"Cytotoxic T Cells Isolated from Ovarian Malignant Ascites Recognize a Peptide Derived from the HER-2
eu Proto-oncogene" Constatin G. Ioannides et al. Cellular Immunology, 151, 225-234 (1993).
"CTL Clones Isolated From Ovarian Tumor Infiltrating Lymphocytes Can Recognize Peptides With Sequences Corresponding To The HER2/NEU Gene Product" Ionnides C. G. et al. 1992 FASEB Meeting Apr. 2-9.
"T-cell Recognition Of Ovarian Cancer" George E. Peoples et al. Surgery 227-234 Aug. 1993.
"Allele-Specific Motifs Revealed By Sequencing Of Self-Peptides Eluted From MHC Molecules" Falk et al. Nature vol. 351 290-296 May 23, 1991.
"HLA-A2 Presents Shared Tumor-Associated Antigens Derived From Endogenous Proteins In Ovarian Cancer" George E. Peoples et al. The Journal of Immunology vol. 151, 5481-5491, No. 10 Nov. 15, 1993.
"Cytotoxic T-Cell Clones Isolated From Ovarian Tumour Infiltrating Lymphocytes Recognize Common Determinants on Non-Ovarian Tumour Clones" C. G. Ioannides et al. Scand. J. Immunol. 37, 413-424, 1993.
"Prominent Role of Secondary Anchor Residues In Peptide Binding To HLA-A2.1 Molecules" Jorg Ruppert et al. Cell vol. 71, 929-937, Sep. 10, 1993.
"The Minimum Peptide Epitope From The Influenza Virus Matrix Protein" Maria A. Bednarek et al. The Journal of Immunology vol. 147, 4047-4053, No. 12, Dec. 15, 1991.
"Studies Of The HER-2
eu Proto-oncogene In Human Breast and Ovarian Cancer" Dennis J. Slamon er al. Science, vol. 244, 707-712, 1980.
"Tyrosine Kinase Receptor With Extensive Homology To EGF Receptor Shares Chromosomal Location With neu Oncogene" Lisa Coussens et al. Science vol. 230, 1132-1139, Dec. 6, 1985.
"Similarity Of Protein Encoded By The Human c-erb-B-2 Gene To Epidermal Growth Factor Receptor" Tadashi Yamamoto et al. Nature vol. 319, 230-234, Jan. 16, 1986.
"erbB-2 Is A Potent Oncogene When Overexpressed In NIH/3T3 Cells" Pier Paolo Di Fiore et al. Science vol. 237, 178-182, Jul. 10, 1987.

Affiliated with

Also associated with

Rating

Isolated antigenic oncogene peptide fragments and uses does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Isolated antigenic oncogene peptide fragments and uses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isolated antigenic oncogene peptide fragments and uses will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1056850